Merus (MRUS) Competitors $66.46 +0.62 (+0.93%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. SMMT, GMAB, VTRS, RDY, ASND, QGEN, MRNA, BBIO, VRNA, and ELANShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Summit Therapeutics (NASDAQ:SMMT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do institutionals & insiders believe in SMMT or MRUS? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 3.7% of Merus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer SMMT or MRUS? Summit Therapeutics presently has a consensus target price of $33.31, indicating a potential upside of 38.72%. Merus has a consensus target price of $88.75, indicating a potential upside of 33.55%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Does the media prefer SMMT or MRUS? In the previous week, Summit Therapeutics had 3 more articles in the media than Merus. MarketBeat recorded 15 mentions for Summit Therapeutics and 12 mentions for Merus. Summit Therapeutics' average media sentiment score of 1.10 beat Merus' score of 1.06 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SMMT or MRUS more profitable? Summit Therapeutics has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Merus -685.64%-50.28%-42.00% Which has preferable valuation and earnings, SMMT or MRUS? Merus has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K25,479.76-$221.32M-$1.01-23.77Merus$36.13M139.11-$215.33M-$5.50-12.08 Which has more volatility and risk, SMMT or MRUS? Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. SummaryMerus beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.03B$3.09B$5.69B$9.67BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-12.0921.0782.8526.35Price / Sales139.11403.97551.97112.92Price / CashN/A43.5325.6628.92Price / Book7.029.8711.596.08Net Income-$215.33M-$54.01M$3.27B$265.75M7 Day Performance-0.61%0.15%0.48%-0.05%1 Month Performance1.37%9.41%8.68%5.82%1 Year Performance30.33%8.06%59.42%17.97% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.0619 of 5 stars$66.46+0.9%$88.75+33.5%+29.1%$5.03B$36.13M-12.0937Positive NewsSMMTSummit Therapeutics2.5046 of 5 stars$26.27+0.3%$32.85+25.0%+82.6%$19.46B$700K0.00110Positive NewsAnalyst ForecastGap DownGMABGenmab A/S3.6812 of 5 stars$24.31-1.4%$37.60+54.7%-10.5%$15.81B$3.12B14.412,682Positive NewsGap UpVTRSViatris1.7884 of 5 stars$10.55-0.9%$10.40-1.4%-12.7%$12.42B$14.74B4.4232,000RDYDr. Reddy's Laboratories2.8697 of 5 stars$14.46-0.4%$16.95+17.3%-15.0%$12.11B$3.81B21.9927,811News CoveragePositive NewsASNDAscendis Pharma A/S2.5464 of 5 stars$190.37-2.0%$243.36+27.8%+40.3%$11.89B$393.54M0.001,017News CoveragePositive NewsQGENQIAGEN3.8021 of 5 stars$48.92-1.6%$49.69+1.6%+4.7%$11.06B$1.98B21.205,765News CoveragePositive NewsMRNAModerna4.5094 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$10.55B$3.24B0.005,800BBIOBridgeBio Pharma4.1755 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$221.90M0.00400Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2361 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$9.13B$42.28M0.0030News CoveragePositive NewsELANElanco Animal Health2.7654 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.44B19.909,000Positive News Related Companies and Tools Related Companies Summit Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors QIAGEN Competitors Moderna Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHave You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts